Canada Markets closed

PsyBio Therapeutics Corp. (PSYBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1600-0.0047 (-2.85%)
At close: 03:53PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.1647
Open0.1600
BidN/A x N/A
AskN/A x N/A
Day's Range0.1600 - 0.1732
52 Week Range0.1527 - 0.7900
Volume26,555
Avg. Volume77,234
Market Cap18.262M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • CNW Group

    PsyBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

    PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focusing on discovering and developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced that Evan Levine, Chief Executive Officer and Chairman, will present at the H.C. Wainwright Bioconnect Conference.

  • CNW Group

    PsyBio Therapeutics Establishes Research and Development Laboratory to Facilitate Portfolio Development Progress

    PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced that it has expanded its ongoing relationship with Miami University in Oxford, Ohio ("Miami University") by leasing dedicated research and development ("R&D") laboratory space.

  • CNW Group

    PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States Food and Drug Administration

    PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced the successful completion of its initial pre-Investigational New Drug ("IND") application meeting with the United States Food and Drug Administration ("FDA") as part of the regulatory submission process.